Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Thiamine Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.85 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | TKT | P29401 | 12/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiamine Ion SCHEMBL219978 | 0.99 | HSP90AA1 (0.83) | HSP90AA1TDP1TKTLMNAKDM4E | |
| Thiamine Ion SCHEMBL16829708 | 0.99 | HSP90AA1 (0.83) | HSP90AA1TDP1TKTLMNAKDM4E | |
| Thiamine Ion SCHEMBL8813131 | 0.99 | HSP90AA1 (0.83) | HSP90AA1TDP1TKTLMNAKDM4E | |
| Thiamine Ion SCHEMBL8813125 | 0.98 | HSP90AA1 (0.82) | HSP90AA1TDP1TKTLMNAKDM4E | |
| Thiamine Ion SCHEMBL27576184 | 0.96 | HSP90AA1 (0.85) | HSP90AA1TDP1TKTLMNAKDM4E | |
| Thiamine Ion SCHEMBL219977 | 0.96 | HSP90AA1 (0.89) | HSP90AA1TDP1TKTLMNAKDM4E | |
| Thiamine Ion SCHEMBL29195374 | 0.95 | HSP90AA1 (0.87) | HSP90AA1TDP1TKTLMNAKDM4E | |
| Thiamine Ion SCHEMBL219976 | 0.95 | HSP90AA1 (0.87) | HSP90AA1TDP1TKTLMNAKDM4E | |
| Thiamine Ion SCHEMBL16829707 | 0.95 | HSP90AA1 (0.87) | HSP90AA1TDP1TKTLMNAKDM4E | |
| Thiamine Ion SCHEMBL16829706 | 0.94 | HSP90AA1 (0.85) | HSP90AA1TDP1TKTLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210196641-A1 | Soft Capsule Film Composition | FUJI CAPSULE CO., LTD. (JP) | 2021-07-01 | — | — | US | disclosed |
| EP-3785707-A1 | SOFT CAPSULE FILM COMPOSITION | Fuji Capsule Co., Ltd. (JP) | 2021-03-03 | — | — | EP | disclosed |
| EP-3398585-B1 | EXTERNAL DERMAL COMPOSITION FOR ANTI-AGEING AND METHOD FOR PRODUCING THE SAME | HAYASHIBARA CO (JP) | 2020-02-26 | — | — | EP | disclosed |
| US-20190008747-A1 | EXTERNAL DERMAL COMPOSITION FOR ANTI-AGEING AND METHOD FOR PRODUCING THE SAME | Hayashibara Co., Ltd. (JP) | 2019-01-10 | — | — | US | disclosed |
| EP-3398585-A1 | EXTERNAL DERMAL COMPOSITION FOR ANTI-AGEING AND METHOD FOR PRODUCING THE SAME | Hayashibara Co., Ltd. (JP) | 2018-11-07 | — | — | EP | disclosed |
| US-10111822-B2 | External dermal composition for anti-ageing and method for producing the same | Hayashibara Co., Ltd. (JP) | 2018-10-30 | — | — | US | disclosed |
| EP-2939657-B1 | SKIN-EXTERIOR ANTI-AGEING COMPOSITION AND PRODUCTION METHOD THEREFOR | HAYASHIBARA CO (JP) | 2018-08-08 | — | — | EP | disclosed |
| US-20150342854-A1 | EXTERNAL DERMAL COMPOSITION FOR ANTI-AGEING AND METHOD FOR PRODUCING THE SAME | Hayashibara Co., Ltd. (JP) | 2015-12-03 | — | — | US | disclosed |
| EP-2939657-A1 | SKIN-EXTERIOR ANTI-AGEING COMPOSITION AND PRODUCTION METHOD THEREFOR | Hayashibara Co., Ltd. (JP) | 2015-11-04 | — | — | EP | disclosed |
| EP-1570839-B1 | COMPOSITION FOR PREPARATION FOR EXTERNAL USE ON SKIN AND METHOD OF USING THE SAME | KOSE CORP (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-20080058400-A1 | Skin external preparation | FUJIFILM CORPORATION | 2008-03-06 | — | — | US | disclosed |
| US-20060147397-A1 | Composition for preparation for external use on skin and method of using the same | KOSE CORPORATION (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1570839-A1 | COMPOSITION FOR PREPARATION FOR EXTERNAL USE ON SKIN AND METHOD OF USING THE SAME | Kosé Corporation (JP) | 2005-09-07 | — | — | EP | disclosed |
| EP-1043028-B1 | PHYTASE FOR PREVENTING OR TREATING MASTITIS | KYOWA HAKKO KOGYO KK (JP) | 2004-10-20 | — | — | EP | disclosed |
| US-6787134-B1 | Methods for preventing/remedying mastitis | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-07 | — | — | US | disclosed |
| EP-1043028-A1 | METHOD FOR PREVENTING/REMEDYING MASTITIS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2000-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060147397-A1 | Composition for preparation for external use on skin and method of using the same | S100A6, CUTA, CA6 | HSP90AA1 1741/4885TDP1 4022/4885TKT 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.